215 related articles for article (PubMed ID: 32515543)
21. Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial.
Bolli GB; Riddle MC; Bergenstal RM; Wardecki M; Goyeau H; Home PD;
Diabetes Metab; 2017 Sep; 43(4):351-358. PubMed ID: 28622950
[TBL] [Abstract][Full Text] [Related]
22. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
Hemmingsen B; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
[TBL] [Abstract][Full Text] [Related]
23. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).
Yki-Järvinen H; Bergenstal R; Ziemen M; Wardecki M; Muehlen-Bartmer I; Boelle E; Riddle MC;
Diabetes Care; 2014 Dec; 37(12):3235-43. PubMed ID: 25193531
[TBL] [Abstract][Full Text] [Related]
24. Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM.
Roussel R; Ritzel R; Boëlle-Le Corfec E; Balkau B; Rosenstock J
Diabetes Metab; 2018 Nov; 44(5):402-409. PubMed ID: 29548798
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Asia Pacific insulin-naïve people with type 2 diabetes: The EDITION AP randomized controlled trial.
Ji L; Kang ES; Dong X; Li L; Yuan G; Shang S; Niemoeller E;
Diabetes Obes Metab; 2020 Apr; 22(4):612-621. PubMed ID: 31797549
[TBL] [Abstract][Full Text] [Related]
26. Fasting C-peptide, a biomarker for hypoglycaemia risk in insulin-naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL.
Landgraf W; Owens DR; Frier BM; Zhang M; Bolli GB
Diabetes Obes Metab; 2020 Mar; 22(3):315-323. PubMed ID: 31608548
[TBL] [Abstract][Full Text] [Related]
27. The effect of concomitant DPPIVi use on glycaemic control and hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes: A patient-level meta-analysis of EDITION 2 and 3.
Yale JF; Pettus JH; Brito-Sanfiel M; Lavalle-Gonzalez F; Merino-Trigo A; Stella P; Chevalier S; Buzzetti R
PLoS One; 2018; 13(1):e0190579. PubMed ID: 29370218
[TBL] [Abstract][Full Text] [Related]
28. Comparison of insulin glargine 300 U/mL versus glargine 100 U/mL on glycemic control and hypoglycemic events in East Asian patients with type 2 diabetes: A Patient-level meta-analysis of phase 3 studies.
Ji L; Bi Y; Ye S; Huang Y; Zhang X; Shang S; Cui N; Yin H; Zhang M
Diabetes Res Clin Pract; 2021 Jun; 176():108848. PubMed ID: 33945841
[TBL] [Abstract][Full Text] [Related]
29. Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study.
Cheng A; Harris S; Giorgino F; Seufert J; Ritzel R; Khunti K; Lauand F; Melas-Melt L; Westerbacka J; Bosnyak Z; Rosenstock J
Diabetes Obes Metab; 2020 Mar; 22(3):346-354. PubMed ID: 31646724
[TBL] [Abstract][Full Text] [Related]
30. Sustained glycaemic control and less nocturnal hypoglycaemia with insulin glargine 300U/mL compared with glargine 100U/mL in Japanese adults with type 1 diabetes (EDITION JP 1 randomised 12-month trial including 6-month extension).
Matsuhisa M; Koyama M; Cheng X; Sumi M; Riddle MC; Bolli GB; Hirose T;
Diabetes Res Clin Pract; 2016 Dec; 122():133-140. PubMed ID: 27835765
[TBL] [Abstract][Full Text] [Related]
31. A review of the safety and efficacy data for insulin glargine 300 units/ml, a new formulation of insulin glargine.
Dailey G; Lavernia F
Diabetes Obes Metab; 2015 Dec; 17(12):1107-14. PubMed ID: 26139151
[TBL] [Abstract][Full Text] [Related]
32. Insulin Glargine 300 U/mL Therapy in Children and Adolescents with Type 1 Diabetes.
Maffeis C; Rabbone I
Paediatr Drugs; 2022 Sep; 24(5):499-512. PubMed ID: 35881330
[TBL] [Abstract][Full Text] [Related]
33. Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: A review of the DELIVER programme.
Blonde L; Bailey T; Sullivan SD; Freemantle N
Diabetes Obes Metab; 2021 Aug; 23(8):1713-1721. PubMed ID: 33881797
[TBL] [Abstract][Full Text] [Related]
34. Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial.
Bolli GB; Cheng A; Charbonnel B; Aroda VR; Westerbacka J; Bosnyak Z; Boëlle-Le Corfec E; Rosenstock J
Diabetes Obes Metab; 2021 Jul; 23(7):1588-1593. PubMed ID: 33687748
[TBL] [Abstract][Full Text] [Related]
35. Hypoglycaemia as a function of HbA1c in type 2 diabetes: Insulin glargine 300 U/mL in a patient-level pooled analysis of EDITION 1, 2 and 3.
Bonadonna RC; Yale JF; Brulle-Wohlhueter C; Boëlle-Le Corfec E; Choudhary P; Bailey TS
Diabetes Obes Metab; 2019 Mar; 21(3):715-719. PubMed ID: 30414260
[TBL] [Abstract][Full Text] [Related]
36. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1).
Riddle MC; Bolli GB; Ziemen M; Muehlen-Bartmer I; Bizet F; Home PD;
Diabetes Care; 2014 Oct; 37(10):2755-62. PubMed ID: 25078900
[TBL] [Abstract][Full Text] [Related]
37. Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mild-to-moderate renal impairment.
Javier Escalada F; Halimi S; Senior PA; Bonnemaire M; Cali AMG; Melas-Melt L; Karalliedde J; Ritzel RA
Diabetes Obes Metab; 2018 Dec; 20(12):2860-2868. PubMed ID: 30003642
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcomes in high-hypoglycaemia-risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first-generation basal insulin analogue in the United States : Results from the DELIVER High Risk real-world study.
Sullivan SD; Freemantle N; Gupta RA; Wu J; Nicholls CJ; Westerbacka J; Bailey TS
Endocrinol Diabetes Metab; 2022 Jan; 5(1):e00306. PubMed ID: 34807513
[TBL] [Abstract][Full Text] [Related]
39. A pragmatic randomized clinical trial of insulin glargine 300 U/mL vs first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 6-month outcomes of the ACHIEVE Control study.
Meneghini LF; Sullivan SD; Oster G; Busch R; Cali AMG; Dauchy A; Gill J; Bailey TS
Diabetes Obes Metab; 2020 Nov; 22(11):2004-2012. PubMed ID: 32729217
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of a morning injection of insulin glargine 300 units/mL versus insulin glargine 100 units/mL in adult patients with type 1 diabetes: A multicentre, randomized controlled trial using continuous glucose monitoring.
Pettus J; Gill J; Paranjape S; Stewart J; Malla S; Edelman S; Bergenstal RM; Bode B
Diabetes Obes Metab; 2019 Aug; 21(8):1906-1913. PubMed ID: 30993855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
